LXRX - Lexicon Pharmaceuticals, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
The Woodlands,
United States
Type: Equity
LXRX price evolution
LXRX
| (in millions $) | 31 Mar 2023 | 31 Jan 2023 | 30 Sep 2022 | 30 Jun 2022 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $26 | $46.34 | $18.83 | $21.45 |
| Short term investments | $79.94 | $92.01 | $117.37 | $40.52 |
| Net receivables | $0.26 | $0.03 | $0.04 | $0.03 |
| Inventory | ||||
| Total current assets | $109.55 | $140.87 | $139.06 | $64.9 |
| Long term investments | ||||
| Property, plant & equipment | $8.63 | $4.37 | $0.93 | $1.03 |
| Goodwill & intangible assets | $44.54 | $44.54 | $44.54 | $44.54 |
| Total noncurrent assets | $53.17 | $53.43 | $52.62 | $47.43 |
| Total investments | $79.94 | $92.01 | $117.37 | $40.52 |
| Total assets | $162.72 | $194.3 | $191.69 | $112.33 |
| Current liabilities | ||||
| Accounts payable | $10.31 | $10.39 | $9.43 | $7.35 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $20.37 | $23.17 | $18.45 | $16.86 |
| Long term debt | $54.3 | $48.58 | $23.78 | $23.63 |
| Total noncurrent liabilities | $54.3 | $54 | $29.22 | $24.63 |
| Total debt | $54.3 | $54 | $23.78 | $23.63 |
| Total liabilities | $74.67 | $77.17 | $47.67 | $41.49 |
| Shareholders' equity | ||||
| Retained earnings | -$1621.65 | -$1589.72 | -$1559.23 | -$1535.84 |
| Other shareholder equity | -$0.16 | -$0.43 | -$0.49 | -$0.15 |
| Total shareholder equity | $88.05 | $117.12 | $144.02 | $70.83 |
| (in millions $) | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $46.34 | $64.06 | $126.26 | $36.11 |
| Short term investments | $92.01 | $22.68 | $26.01 | $235.55 |
| Net receivables | $0.03 | $0.01 | $0.4 | $56.53 |
| Inventory | $4.24 | |||
| Total current assets | $140.87 | $88.92 | $157.72 | $337.75 |
| Long term investments | ||||
| Property, plant & equipment | $4.37 | $1.18 | $0.29 | $14.05 |
| Goodwill & intangible assets | $44.54 | $44.54 | $44.54 | $64.26 |
| Total noncurrent assets | $53.43 | $47.99 | $46.07 | $79.96 |
| Total investments | $92.01 | $22.68 | $26.01 | $235.55 |
| Total assets | $194.3 | $136.91 | $203.79 | $417.71 |
| Current liabilities | ||||
| Accounts payable | $10.39 | $9.15 | $5.47 | $12.18 |
| Deferred revenue | ||||
| Short long term debt | $11.65 | $11.01 | ||
| Total current liabilities | $23.17 | $22.12 | $46.81 | $65.34 |
| Long term debt | $48.58 | $234.17 | ||
| Total noncurrent liabilities | $54 | $1.19 | $0.61 | $235.27 |
| Total debt | $54 | $11.65 | $245.18 | |
| Total liabilities | $77.17 | $23.31 | $47.42 | $300.61 |
| Shareholders' equity | ||||
| Retained earnings | -$1589.72 | -$1487.78 | -$1400.02 | -$1341.44 |
| Other shareholder equity | -$0.43 | -$0.01 | -$0.01 | $0.08 |
| Total shareholder equity | $117.12 | $113.59 | $156.37 | $117.1 |
| (in millions $) | 31 Mar 2023 | 31 Dec 2022 | 30 Sep 2022 | 30 Jun 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.02 | $0.03 | $0.04 | $0.04 |
| Cost of revenue | ||||
| Gross Profit | $0.02 | $0.03 | $0.04 | $0.04 |
| Operating activities | ||||
| Research & development | $12.03 | $13.98 | $10.56 | $13.36 |
| Selling, general & administrative | $19.14 | $16.33 | $12.58 | $10.69 |
| Total operating expenses | $31.17 | $30.31 | $23.13 | $24.04 |
| Operating income | -$31.14 | -$30.28 | -$23.09 | -$24.01 |
| Income from continuing operations | ||||
| EBIT | -$30.11 | -$29.39 | -$22.52 | -$23.88 |
| Income tax expense | ||||
| Interest expense | $1.82 | $1.1 | $0.86 | $0.7 |
| Net income | ||||
| Net income | -$31.93 | -$30.49 | -$23.39 | -$24.59 |
| Income (for common shares) | -$31.93 | -$30.49 | -$23.39 | -$24.59 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.14 | $0.3 | $24 | $322.07 |
| Cost of revenue | $1.93 | $3.23 | ||
| Gross Profit | $0.14 | $0.3 | $22.07 | $318.84 |
| Operating activities | ||||
| Research & development | $52.82 | $55.05 | $153.62 | $91.92 |
| Selling, general & administrative | $48.08 | $32.34 | $47.23 | $56.84 |
| Total operating expenses | $100.9 | $87.39 | $69.87 | $177.4 |
| Operating income | -$100.76 | -$87.09 | -$47.8 | $141.44 |
| Income from continuing operations | ||||
| EBIT | -$99.16 | -$86.96 | -$44.03 | $144.79 |
| Income tax expense | -$6.01 | |||
| Interest expense | $2.78 | $0.8 | $14.54 | $20.68 |
| Net income | ||||
| Net income | -$101.94 | -$87.76 | -$58.57 | $130.13 |
| Income (for common shares) | -$101.94 | -$87.76 | -$58.57 | $130.13 |
| (in millions $) | 31 Mar 2023 | 31 Dec 2022 | 30 Sep 2022 | 30 Jun 2022 |
|---|---|---|---|---|
| Net income | -$31.93 | -$30.49 | -$23.39 | -$24.59 |
| Operating activities | ||||
| Depreciation | $0.11 | $0.1 | $0.11 | $0.11 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $3.42 | $3.27 | $2.65 | $2.83 |
| Total cash flows from operations | -$31.61 | -$21.57 | -$19.44 | -$24.42 |
| Investing activities | ||||
| Capital expenditures | -$0.25 | -$1.25 | -$0 | |
| Investments | $12.34 | $25.42 | -$77.19 | -$13.65 |
| Total cash flows from investing | $12.09 | $24.17 | -$77.2 | -$13.65 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$0.82 | -$0.06 | $94.27 | |
| Net borrowings | $24.97 | -$0.25 | ||
| Total cash flows from financing | -$0.82 | $24.91 | $94.02 | |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$20.34 | $27.51 | -$2.62 | -$38.07 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Net income | -$101.94 | -$87.76 | -$58.57 | $130.13 |
| Operating activities | ||||
| Depreciation | $0.43 | $0.29 | $2.93 | $3.65 |
| Business acquisitions & disposals | $160.38 | |||
| Stock-based compensation | $11.52 | $10.58 | $13.27 | $14.22 |
| Total cash flows from operations | -$88.85 | -$87.02 | -$142.97 | $113.81 |
| Investing activities | ||||
| Capital expenditures | -$1.33 | -$1.22 | $10.93 | -$0.07 |
| Investments | -$69.75 | $3.33 | $209.44 | -$155.78 |
| Total cash flows from investing | -$71.08 | $2.11 | $380.76 | -$155.85 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $93.34 | $34.41 | $68.94 | -$0.94 |
| Net borrowings | $48.87 | -$11.7 | -$216.58 | -$1.28 |
| Total cash flows from financing | $142.21 | $22.71 | -$147.64 | -$2.23 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$17.72 | -$62.2 | $90.15 | -$44.27 |
News
Fundamentals
| Market cap | $521.30M |
|---|---|
| Enterprise value | $549.59M |
| Shares outstanding | 189.56M |
| Revenue | $126.00K |
|---|---|
| EBITDA | -$105.48M |
| EBIT | -$105.91M |
| Net Income | -$110.40M |
| Revenue Q/Q | -35.14% |
| Revenue Y/Y | -59.09% |
| P/E ratio | -4.72 |
|---|---|
| EV/Sales | 4.36K |
| EV/EBITDA | -5.21 |
| EV/EBIT | -5.19 |
| P/S ratio | 4.14K |
| P/B ratio | 5.91 |
| Book/Share | 0.47 |
| Cash/Share | 0.14 |
| EPS | -$0.58 |
|---|---|
| ROA | -66.81% |
| ROE | -105.14% |
| Debt/Equity | 0.66 |
|---|---|
| Net debt/EBITDA | -0.46 |
| Current ratio | 5.38 |
| Quick ratio | 5.38 |